Observational Study With CICR-NAM as a Food for Special Medicinal Purposes in Post-COVID Syndrome (PCS)

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type

Interventional

Phase

Not applicable

Age range

18 years - Not specified

Sex eligible

All sexes

Healthy volunteers

Not accepted

Participants

100 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

In patients with post-COVID syndrome, changes in tryptophan metabolism, energy metabolism, and the gut microbiome may occur. In an earlier nutritional study, patients with COVID-19 recovered their physical performance more quickly when taking nicotinamide (vitamin B3). Patients who responded to nicotinamide also developed post-COVID syndrome less frequently. At the University Hospital Schleswig-Holstein in Kiel, special nicotinamide tablets (CICR-NAM) were developed that release the active substance selectively in the lower intestine and have been shown to be very well tolerated in several studies.

Patients with post-COVID syndrome and documented tryptophan deficiency may therefore take one tablet (500 mg) of CICR-NAM daily for up to approximately 4 months as a food for special medicinal purposes within the therapy groups of the outpatient clinic for patients with post-COVID syndrome at the University Hospital Schleswig-Holstein in Kiel. This intake is far below the Upper Level defined by the European Food Safety Authority for lifelong daily intake (900 mg per day). Therefore, there are no safety concerns. CICR-NAM intake is intended to complement the therapy group programme by supporting energy metabolism.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

• all sexes;
• minimum age 18 years; no upper age limit;
• post-COVID syndrome (PCS)
• serum tryptophan \<55 µmol/L (UKSH reference range: 48-109 µmol/L);
• participation in the therapy groups of the PCS outpatient clinic at UKSH Campus Kiel.

Exclusion Criteria:

• Known allergies or intolerances to any component of CICR-NAM;
• inability to provide informed consent;
• pregnancy or breastfeeding;
• severe comorbid disease (especially renal insufficiency, uncontrolled autoimmune diseases, liver disease, or malignancy);
• long-term use of higher doses of medications that raise gastric pH (for example proton pump inhibitors, H2 receptor antagonists, or antacids), as an increase in pH toward approximately 7 may cause premature release of nicotinamide from CICR-NAM;
• use of supplements containing more than 20 mg nicotinamide, nicotinamide riboside, nicotinamide mononucleotide, nicotinic acid, or NAD+ per daily dose.

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Not applicable

Masking

No masking

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Study team and timeline

Lead sponsor

University Hospital Schleswig-Holstein

Study start

Sep 8, 2026 Actual

Primary completion

Jun 30, 2028 Estimated

Study completion

Jun 30, 2028 Estimated

First posted

Sep 1, 2026 Actual

Last updated

Nov 10, 2026 Actual

Official study contacts